Straits Times Index
3,289.42 -23.93 (-0.72%) S&P 500
5,304.59 +57.91 (+1.10%) Dow
39,861.29 +303.18 (+0.77%) Nasdaq
16,746.69 +235.51 (+1.43%) Bitcoin USD
65,923.79 +4,464.76 (+7.26%) CMC Crypto 200
1,379.37 +111.43 (+8.77%)
BIIB Jul 2024 210.000 put
| Previous close | 4.1000 |
| Open | 2.3000 |
| Bid | 1.6500 |
| Ask | 2.3500 |
| Strike | 210.00 |
| Expiry date | 2024-07-19 |
| Day's range | 1.9300 - 2.3000 |
| Contract range | N/A |
| Volume | |
| Open interest | 321 |
ZacksBiogen (BIIB) Partner Begins Filing for Leqembi SC Autoinjector
Biogen (BIIB) and Eisai start the rolling submission of a biologics license application to the FDA for Leqembi subcutaneous autoinjector as a weekly maintenance dosing regimen for early Alzheimer's disease.
- Reuters
UPDATE 1-Eisai starts rolling submission for injectable version of Alzheimer's drug with US FDA
Eisai and partner Biogen said on Tuesday that the Japanese drugmaker has begun submitting data on a rolling basis to the US health regulator for a marketing application of a subcutaneous form of their Alzheimer's disease drug Leqembi. The companies are seeking the Food and Drug Administration's (FDA) approval of a weekly dose of Leqembi to be given as an under-the-skin injection. Under a rolling submission the regulator assesses the data as and when it becomes available, and the process continues until there is enough data for a formal marketing application.
GlobeNewswireEisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status
TOKYO and CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that Eisai has initiated the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand name: LEQEMBI®) subcutaneous autoinjector for weekly maintenance dos
